• Lead trial counsel for IOENGINE in cases involving secure USB storage devices. Two juries found all asserted claims of IOENGINE’s patent valid and infringed, and credited IOENGINE’s founder as the sole inventor of the patented technology, collectively awarding over US$12 million in damages for past infringement.
    • Obtained a complete dismissal with prejudice of all allegations against Daiichi Sankyo and its U.S. subsidiary as lead counsel in the Lipitor “pay for delay” litigation. The decision was affirmed by the Third Circuit Court of Appeals and the Supreme Court denied certiorari.
    • Daiichi Sankyo in an ICC arbitration seated in Singapore, stemming from its acquisition of a majority interest in Ranbaxy. The arbitral tribunal found that the former owners of Ranbaxy fraudulently concealed and misrepresented the nature and severity of FDA and DOJ investigations of Ranbaxy, and awarded Daiichi Sankyo the rupee-denominated equivalent of over US$525 million, including fees, interest and costs.
    • Daiichi Sankyo (formerly Daiichi Pharmaceutical) in litigation to enforce Daiichi's patent on its multibillion dollar-dollar-per-year anti-ineffective LEVAQUIN® (levofloxacin) against numerous generic filers.  The case against the first generic filer was won after a two month trial in the Northern District of West Virginia and affirmed by the Federal Circuit Court of Appeals. Cases against additional generic filers were resolved by successful motions for summary judgment.
    • Daiichi Sankyo in Hatch-Waxman challenges to BENICAR® (olmesartan), BENICAR® HCT (olmesartan / hydrochlorothiazide) and AZOR® (amlodipine / olmesartan) products. The cases were consolidated and tried to successful outcome in the District of New Jersey.  The Federal Circuit Court of Appeals affirmed.
    • Eli Lilly in a challenge to the Cabilly patents over Lilly’s cancer treatment ERBITUX® (cetuximab).
    • Human Genome Sciences in a series of patent and antitrust cases over HGS’s BENLYSTA® (belimumab), the first FDA approved treatment for systemic lupus in over 50 years.
    • Obtained a preliminary injunction for Biosynexus, Inc. in a licensing dispute  related to the development of a monoclonal antibody therapy for the prevention of staphylococcal infections in premature babies.

    Includes matters handled at Dechert or prior to joining the firm.

    • 14th Annual Paragraph IV Disputes Conference — Virtual (October 6-7, 2020)

      Speaker, "Devising Strategies for Proving Infringement and Defending Validity" panel.
    • 35th Annual Joint Patent Practice Seminar — New York, NY (May 2, 2019)

      Speaker, "Hot Topics re. §101 and §102" breakout session.